) received positive news with Opsumit receiving approval as
monotherapy or in combination with another PAH therapy in the EU
for the long-term treatment of patients suffering from pulmonary
arterial hypertension (PAH WHO Functional Class II to III) to
delay disease progression. The first EU launch is planned for
Germany in Feb 2014.
The approval did not come as a surprise as Actelion received a
positive opinion from the Committee for Medicinal Products for
Human Use (CHMP) for Opsumit in Oct 2013.
The approval was based on data from the SERAPHIN study.
Results from the SERAPHIN study showed that the risk of a
morbidity/mortality event was cut by 45% in patients who were
administered Opsumit compared to those on placebo. The study also
showed a reduction in the risk of PAH related hospitalization and
death by 50%.
We note that Opsumit was approved by the U.S. Food and Drug
Administration on Oct 18, 2013 and it was launched in Nov 2013.
Health Canada approved Opsumit in Nov 2013..
The approval of Opsumit has strengthened Actelion's
cardiovascular portfolio. However, the PAH market looks
extremely competitive with the presence of Adempas, Revatio and
We note that Opsumit is being evaluated for the treatment of
glioblastoma (phase I). Opsumit is also being evaluated in a
pivotal phase III DUAL program in patients suffering from digital
ulcers associated with systemic sclerosis. The independent Data
Monitoring Committee (DMC) has recommended the termination of the
phase III DUAL-2 study as it feels a positive primary outcome
measure is not likely to result from additional data. However,
the DUAL-1 study will be continued as planned.
Actelion carries a Zacks Rank #1 (Strong Buy). Investors may
also consider companies like
Questcor Pharmaceuticals Inc.
) all of which carry a comparable Zacks Rank #1.
ACTELION LTD (ALIOF): Get Free Report
ENANTA PHARMA (ENTA): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.